Search results for: rare disease

NICEs new methods and processes manual

The National Institute for Health and Care Excellence (NICE) on 31st January 2022 published its new ...

Read more
PMA Perspectives Q1 2022

We hope you’ve had a wonderful start to the New Year and we’d love to welcome you to our fourth ...

Read more
The end of higher drug prices in the US

In the US, an Act recently passed through the House of Representatives which plans to expand afforda...

Read more
PMA Insights: Week 51 2021

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Orphan drug status benefit

The purpose of this study is to compare the assessments of orphan and non-orphan drugs by NICE.

Read more
PMA Insights: Week 39 2021

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
NICE remodel plans for January 2022

NICE’s remodel plans focus on delivering faster and fairer access to treatments by optimising appr...

Read more
New Innovative Medicines Fund

NHS England, the UK’s publicly funded healthcare system, will be introducing a £340m fund dedicat...

Read more
Market Access News Summary

We’ve prepared a summary of our key market access blogs and news articles from the second quarter ...

Read more
Gene therapy market access and pricing trends

A dive into the complex and expensive world of gene therapy pricing and access.

Read more
Older
Newer

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.

Talk to an expert

Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.​

Get in touch